



Antiadrenergics

Lecture
Tomáš Goněc

2020



Antiadrenergics

direct – competitive inhibitors on NA binding site

indirect – inhibitors of release/uptake of NA

blocking of adrenergic receptor causes:

- vasodilation and blood pressure decrease
- bradycardia (heart-rate decrease)
- increase of uterus tonicity
- prolactin release inhibition




Antiadrenergics

Antiadrenergics are used in therapy as:


- antihypertensives
- vasodilators
- antiarrhythmics
- antimigranotics
- uterotonics

α -blockers (non-selective)


Natural drugs – ergot alkaloids



lysergic acid



isolysergic acid




R=H, OH
clavine alkaloids

Three types of alkaloid. Isolysergic acid is optical isomer of lysergic acid. Clavine is without 9-10 double bond and carboxyl.

α -blockers (non-selective)

Ergotamine, Dihydroergotamine

- α antagonistic, 5HT, D agonistic effect
- therapy of migraine



Vasoconstrictors! Dihydroergotamine is without 9-10 double bond and is intended for nasal administration (rapid onset)

α -blockers (non-selective)

Dihydroergotoxine


- α_1 , 5HT antagonistic, D agonistic effect
- mixture of dihydroergocristine, dihydroergocryptine and dihydroergocornine
- therapy of insufficient limbs perfusion, insufficient CNS perfusion, insufficient internal ear perfusion, Menier disease

Vasodilators!

α -blockers (non-selective)

Tolazoline

- α antagonist, H_2 agonist
- therapy of neonatal pulmonar hypertension




causes selective vasodilation in lungs

α -blockers (non-selective)



Phentolamine

- dominantly α_1 antagonist - vasodilator
- antihypertensive agent
- limited use (hypertension crisis)




weak α_2 antagonist as well – risk of reflexive tachycardia


α_1 -selective blockers



Prazosin
antihypertensive




Terazosin
antihypertensive,
BPH



Doxazosin
antihypertensive,
BPH

Prazosin is not in clinical use, other derivatives possess better safety profiles. Terazosin and doxazosin have longer biological half-time (use 1x a day). Therapy of hypertension and benign prostatic hyperplasia (BPH)


α_1 -selective blockers



Alfuzosin
Uroselective
BPH


Selective decrease of urethral and prostatic tonus. Therapy of BPH

α_1 -selective blockers



Urapidil

also 5HT_{1A} agonist
arterial hypertension



Tamsulosin

Uroselective
BPH
urinary incontinence


Urapidil is both α_1 antagonist and central 5HT_{1A} agonist – combined central and peripheral antihypertensive effect

Tamsulosin selectively decreases urethral and prostatic tonus, improves bladder function

α_2 -selective blockers


Yohimbine

specific increase of pelvic perfusion
therapy of erectile dysfunction



Alkaloid of Yohimbe tree

Indirectly acting α -blockers



Bretylium tosylate

inhibits noradrenaline release in
neural junction

III.class antidysrhythmic drug



β -blockers

Current Use


Treatment

· Angina pectoris (chest pain associated with lack of oxygen to the heart) · Arrhythmias (irregular heart rhythms) · Heart attack · Heart failure · Hypertension (high blood pressure) · Glaucoma · Migraine


Prevention

· Protects the heart in people who have coronary artery disease · Reduces risk of stroke · Protective prior to non-cardiac surgery in persons at high risk of complications

β -blockers



Aryloxypropanolamines



Arylethanolamines

SAR: (-propoxy-) spacer -O- can be replaced by isosteric
-COO-; -NHCOO- or =C=N- group

R1: isopropyl-, *tert*butyl- or arylalkyl-

R2: various substituents

o-substitution or another ring = non-selective

p-substitution = cardioselectivity

R1 is substituted with lipophilic group – isopropyl, *tert*-butyl or arylalkyl – selectivity towards beta receptors

β -blockers

absolute configuration




FIGURE 10.15 Stereochemical nomenclature for aryloxypropanolamines versus aryloxypropanolamines. The relative positions in space of the four functional groups are the same in the two structures; however, one is designated R and the other S . This is because the introduction of an oxygen atom into the side chain of the aryloxypropanolamine changes the priority of two of the groups used in the nomenclature assignment.

Same space orientation but different R/S name! Different groups priority!

β -blockers

effect variation:

intrinsic sympathomimetic activity (ISA)

compounds with ISA partially stimulates adrenergic receptor, but response is hundred times weaker

membrane stabilizing activity (MSA)


compounds with MSA acts like Na⁺ channel blockers (like local anaesthetics) and such activity is useful for arrhythmia therapy

cardioselectivity

cardioselective compounds prefer myocardial β_1 -adrenergic receptors and has reduced affinity to bronchial β_2 -adrenergic receptors (no bronchial side-effects)

Non-cardioselective betablockers are contraindicated in cardiology (use only for migrain and glaucoma therapy)



non-selective β -blockers without ISA and MSA




Metipranolol – obsolete in cardiology; use for migraine prevention, stress urinary incontinence

Cloranolol, Bufetolol – similar properties, less common

non-selective β -blockers without ISA and MSA



propranolol




indenalol

Propranolol is used in migraine prevention

Indenalol less common, same use

non-selective β -blockers without ISA and MSA




Carteolol – local application for glaucoma therapy

Nadolol – angina pectoris therapy

Bunolol / Levobunolol (pure S isomere) – local application in glaucoma therapy

Tertatolol – used for hypertension therapy


non-selective β -blockers without ISA and MSA



timolol


Local application in glaucoma therapy

non-selective β -blockers with ISA



Pindolol and Bopindolol (prodrug converted to dimethylpindolol) used for hypertension therapy. Use limited to angina pectoris therapy now.


non-selective β -blockers with MSA




oxprenolol

Lipophilic compound passes through blood-brain barrier. Therapy of arrhythmias, angina pectoris

non-selective β -blockers with MSA and ISA




alprenolol



penbutolol

lipophilic compounds pass through blood-brain barrier – cerebral side-effects.
Alprenolol was used for hypertension, penbutolol for angina pectoris therapy.
Obsolent today.

selective β_1 -blockers without ISA and MSA




Atenolol is used for angina pectoris, myocardial infarction, arrhythmia and hypertension therapy.

Metoprolol is widely used in same indications as atenolol, additionally for migraine prevention

Betaxolol possesses some additional Ca^{2+} channel blocking effect – used for therapy of glaucoma, angina pectoris and hypertension

Talinolol was used as antihypertensive agent.


selective β -blockers without ISA and MSA



Celiprolol possess partial beta2 agonistic and alpha2 antagonistic effect. Used for hypertension and angina pectoris therapy.


Acebutolol is used for angina pectoris and arrhythmia therapy

selective β -blockers without ISA and MSA



Nebivolol possess direct vasodilating effect (nitrate-like effect). Therapy of angina pectoris, heart insufficiency.


selective β -blockers with ISA



bunitrolol

Used as antihypertensive and antiarrhythmic agent.



selective β -blockers with MSA



Bisoprolol possess long biological half-time (allows 1x day administration). Used against angina pectoris, arrhythmias, hypertension. Used in long term arrhythmia prophylaxis, after myocardium infarction.

Bevantolol posses additional alpha agonistic and Ca^{2+} channel blocking activity (due to dimethoxy phenylethyl group). No renal side effects- suitable for patients with renal insufficiency. Used for treatment of angina pectoris, arrhythmias, hypertension.

ultra-short-acting β -blockers




Short acting betablockers. Continual intravenous infusion application.

Esmolol – biological half-time 9min, end of effect up to 30 min. Use in acute medicine for treating tachyarrhythmias and during myocardial infarction.

Fleistolol – biological half-time 6min, not in clinical use.


combined α - and β -blockers



Labetalol – not selective beta and selective α_1 blocker. Only intravenous application. Hypertension crisis therapy, gravidity hypertension therapy.


Carvedilol – complex cardiovascular effect. non selective beta, but higher affinity for blocking of β_1 . Selective α_1 blocker. Best mortality index, remedy of first choice. Therapy of heart insufficiency, angina pectoris, heart ischaemia and hypertension.

combined α - and β -blockers



Non selective beta, selective alpha₁ blocker. Used widely in Japan and South Korea.

β -blockers with K^+ channel blocking activity



II. + III. class of antiarrhythmic agents (K^+ channel blocker, non selective beta blocker). Used for therapy of tachyarrhythmias.